China’s NMPA introduces new guidance for COVID-19 drug clinical trials

China’s National Medical Product Administration (NMPA) released on July 2020 a guideline focused on the emergency approval of the new COVID-19 virus drugs and vaccines for sponsors and researchers.

The Office of Human Research Protection Issues Guidance on the Conduct of Clinical trials During COVID-19

On April 8, 2020 the USA’s Office of Human Research Protections (OHRP) released a guidance on  Human Subject Protection Regulations included under regulation 45 CRF part 46, which applies to COVID-19 response. 

Scroll to Top